Myota, Inc.

BLUE BELL, PA · Founded 2017 · CIK 0001740060 · Biotech

Precision prebiotic supplements formulated to modulate gut microbiome composition

myotahealth.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$16M
6 Form D · Feb 2026
8 months since last filing
Contracts
—
No federal contracts on record
Patents
4
2 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,118,039
Private capital raisedForm D · SEC$5,769,537
Private capital raisedForm D · SEC$985,024
Private capital raisedForm D · SEC$2,250,000
Private capital raisedForm D · SEC$1,550,000
Private capital raisedForm D · SEC$3,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1938Centrexion Therapeutics Corp—$189M
1939Aktis Oncology—$175M
1940Quotient Ltd—$92M
1941Myota, Inc.—$16M
1942AXIOMX INC——
1943Sparrow Pharmaceuticals—$73M
1944Iviva Medical—$2.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 15 related persons
  • Gabriel GumbsExecutive Officer
  • Samuel KouryDirector · Executive Officer
  • Ira LubertDirector
  • IRA LUBERTDirector
  • Sergey SlipenchukExecutive Officer
  • SERGEY SLIPENCHUKExecutive Officer
  • Stephen TullmanDirector
  • Neal WalkerDirector
  • James WalkerDirector · Executive Officer
  • NEAL WALKERDirector
  • JAMES WALKERDirector · Executive Officer
  • Jo WebberDirector
  • Neal WebberDirector
  • JO WEBBERDirector
  • A. WRAYDirector · Executive Officer

Patents

USPTO · 2 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.